Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
06/2010
06/29/2010US7745576 Polypeptides having antimicrobial activity and polynucleotides encoding same
06/29/2010US7745574 modulators of Bcl-2 genes and proteins, comprising a mixture of a pro-apoptotic peptide and a cell-penetrating-peptide, that induces apoptosis of mammalian cells expressing Bcl-2 genes or Bcl-2 related proteins, used for for treatment of proliferative diseases and neurodegenerative diseases
06/29/2010US7745572 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
06/29/2010US7745571 Polypetide which suppresses activity of apoptosis stimulating protein of p53 (IASPP) for use in treatment of cancer
06/29/2010US7745488 Therapy for neutropenia as result of radiation therapy; administering colony stimulating factor
06/29/2010US7745485 Inhibiting metastasis of cancer cells by administering a phosphatidyl inositol 3-kinase inhibitor such as Wortmannin or LY294002 (2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one)
06/29/2010US7745444 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
06/29/2010US7745420 stability, high effectiveness and low toxicity; for treating pulmonary/respiratory diseases such as cystic fibrosis, asthma, chronic bronchitis, chronic obstructive lung disease, eosinophilic bronchitis
06/29/2010US7745418 Compositions and methods for inhibiting viral replication
06/29/2010US7745416 Method for in vivo regulation of cardiac muscle contractility
06/29/2010US7745413 Collection of traceable compounds and uses thereof
06/29/2010US7745412 converting an agonist of protein kinase C to an antagonist of protein kinase C; amino acid sequences; crosslinked via an N-terminal Cys-Cys bond to a peptide to facilitate transport cellular uptake
06/29/2010US7745411 Treating anemia as a result of renal failure, AIDS, cancer, organ or bone marrow transplant, chemotherapy or radiotherapy using a peptide of given sequence, comprising angiotensin analogs
06/29/2010US7745410 Bladder tumor-targeting peptide and use thereof
06/29/2010US7745409 Polypeptide comprising the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO:125); activating guanylate cyclase C (GC-C) receptor; gastroesophageal reflux disease, Crohn's disease, ulcerative colitis, Inflammatory bowel disease, dyspepsia, constipation
06/29/2010US7745408 Method of inducing melanogenesis in humans with MC1R variant alleles
06/29/2010US7745407 modulating hepcidin and disease of iron metabolism such as hemochromatosis and anemia of chronic disease; adminstering soluble mammalian hemojuvelin protein
06/29/2010US7745406 Kit which determines concentration of phosphate metabolizing protein and utilizes profile as indicator of hypo/hyperphosphatemic disorders
06/29/2010US7745405 Cancer treatment by administration of a synthetic peptide comprising a sequence of amino acids within the p53 protein and a membrane penetrating leader sequence; fusion proteins for tissue-targeted therapy
06/29/2010US7745404 Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis
06/29/2010US7745403 Methods of treating chemotherapy-induced diarrhea/mucositis using glucagon-like-peptide-2(GLP-2)analogues
06/29/2010US7745402 by administering hemin
06/29/2010US7745401 Use of CAP37 (cationic antimicrobial protein of Mr 37 kDa) peptides and pegylated derivatives to treat fungal infections
06/29/2010US7745400 Prevention and treatment of ocular side effects with a cyclosporin
06/29/2010US7745399 Hsp70 peptide stimulating natural killer (NK) cell activity and uses thereof
06/29/2010US7745398 Soluble ErbB3 and treatment of cancer
06/29/2010US7745397 Containing one or more epitopes recognized by and binding to a BAT monoclonal antibody; cancer vaccines
06/29/2010US7745395 Recombinant protease comprising prostate-specific protease cleavage site and deficient in furin cleavage site for use as therapeutic agent in treatment of cell proliferative disorders; antitumor agents
06/29/2010US7745394 Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases
06/29/2010US7745392 Core moiety such as 1,4,8,11-tetraazacyclotetradecane with a plurality of side chains containing guanidinium groups; conjugated to antigens, peptides, tumor antigens, anticancer agents, antimicrobials
06/29/2010US7745391 Human thrombospondin polypeptide
06/29/2010US7745390 Granulysins; effective against Escherichia, Bacillus, and Salmonella
06/29/2010US7745389 Factor H gene polymorphisms and haplotypes; complement inhibitors
06/29/2010US7745388 Peptide for use in the treatment of cell damage caused by ischemia
06/29/2010US7745387 Use of erythropoietin
06/29/2010US7745216 Methods and reagents for treating glucose metabolic disorders
06/29/2010US7745212 Melanoma antigens and their use in diagnostic and therapeutic methods
06/29/2010US7745193 recombinant nucleotide sequence which codes upon expression for at least a part of a bifunctional hybrid active-site serine beta -lactamase protein
06/29/2010US7745192 Prothrombin activating protein
06/29/2010US7745174 co-expressing two heterotypes of Hepatocyte Growth Factor (HGF) comprising transforming or transfecting to a cell a DNA construct; for prevention and treatment of ischemic and liver disorders
06/29/2010US7745173 Histone deacetylase and methods of use thereof
06/29/2010US7745151 Methods of determining binding between Nogo receptor and p75 neurotrophin receptor
06/29/2010US7745147 use of a monoclonal antibody in the purification of an interferon composition comprising a plurality of interferon alpha subtypes; purification of a crude human leukocyte interferon to greater than 95 percent purity
06/29/2010US7745144 Retro-inverso synthetic peptides; antiproliferative agents; angiogenesis inhibitors
06/29/2010US7745139 for eliminating specifically binding, cell-physiologically active, pathological antibodies in preeclampsia and malign hypertension
06/29/2010US7745114 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
06/29/2010US7745111 Molecular markers of plant embryogenesis
06/29/2010US7745109 Regulation of cell growth by MUC1
06/29/2010US7744927 Methods of promoting hematopoietic and mesenchymal cell proliferation and differentiation
06/29/2010US7744910 Compounds and compositions for delivering active agents
06/29/2010US7744909 Dispersions for the formulation of slightly or poorly soluble agents
06/29/2010US7744907 Ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in the method
06/29/2010US7744906 Chaperone proteins comprising at least one of three specific nucleotide sequences; analgesics; side effect reduction; lastslonger than narcotics; relieving any type of pain
06/29/2010US7744903 Epitopes confirmed to be recognized by T-cells derived from herpetic lesions or uterine cervix; vaccination; host cells
06/29/2010US7744899 Preferentially kills tumor cells and not healthy cells; expresses only one gamma 134.5 gene copy and that comprises an expressibletumor-growth-inhibiting cytokine-encoding DNA; anticarcinogenic agents; antitumor agents; nervous system disorders; immunotherapy;tissue-targeted therapy
06/29/2010US7744896 therapeutic vaccine anti-HIV, anti-AIDS and against tumors and syndromes associated with HIV infection
06/29/2010US7744895 treating a food allergy; orally administer 100 mu g/kg or more of transforming growth factor-beta (TGF- beta ); no side effects
06/29/2010US7744894 Method of treating multiple sclerosis and related t-cell initiated tissue destruction by administering HSA/CD24
06/29/2010US7744891 Using lymphotoxin-beta receptors ligand specific immunoglobulin as therapeutic agent in treatment and prevention of lupus and thrombocytopenia
06/29/2010US7744886 Methods for interfering with rank signaling
06/29/2010US7744885 administering antibodies or antigen-binding fragments which are specific for human tumor necrosis factor- alpha (TNF alpha), used for in vivo medical diagnosis and therapy; immunoassay and immunotherapy
06/29/2010US7744880 cell proliferation-inhibiting activity by ADCC (antibody-dependent cell-mediated cytotoxicity) activity and CDC (complement-dependent cytotoxicity); hepatic cancer
06/29/2010US7744879 Blood-brain barrier targeting antibodies
06/29/2010US7744877 Administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies for treating B cell lymphoma
06/29/2010US7744873 Extracting DNA from a blood or buccal cell sample, PCR, resolution, and identification of differences in sequences between the extracted DNA and PCR primers; drug screening
06/29/2010US7744872 Which bind specifically to polypeptides; for microtiter plate and enzyme linked immunosorbent assay; diagnosis and treatment of canine and human ehrlichiosis; sensitivity and specificity
06/29/2010US7744871 comprising an antibody against an EGF receptor and a vaccine which induces antibodies against EGF or TGF alpha; based on the blockade of receptors with protein kinase activity in tyrosine residues (Receptor Tyrosine Kinases, RTK)
06/29/2010US7744870 A conjugated compound contains antibody or a Fab, and a radiostable therapeutic active agent; for diagnosis/therapy of colorectal cancer; biological conjugated drugs
06/29/2010US7744867 Anticancer, antitumor agents
06/29/2010US7744864 Method for identifying a patient at risk of having difficulty in sustaining a pregnancy
06/29/2010US7744863 inhibiting Th1 immune response of an anti-CD3 monoclonal antibody and IL-5; type I diabetes, multiple sclerosis, rheumatoid arthritis, psoriasis, glomerulonephritis, myasthenia gravis, chronic inflammatory demyelinating neuropathy and inflammatory bowel disease; autoimmune disease
06/29/2010US7744862 Propagating and isolating cell growth factors from prokaryotic systems using ion exchange and reverse phase chromatography; bioreactor and heterologous gene expression
06/29/2010US7744625 Topically applying an effective amount of a formulation containing egg white protein directly onto an amniotic fluid sac of a mammal for sealing a ruptured amniotic membrane
06/29/2010CA2636421C A method of platelet and whole blood storage
06/29/2010CA2575521C Medicinal composition containing diabetes remedy
06/29/2010CA2405521C Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
06/29/2010CA2401942C Pharmaceutical compositions for buccal and pulmonary application
06/29/2010CA2370225C Highly purified gonadotropin compositions and process for preparing them
06/29/2010CA2357114C Use of melatonin in the manufacture of a medicament for treating attention deficit hyperactive disorder
06/29/2010CA2337969C Compound and method for the prevention and/or the treatment of allergy
06/29/2010CA2312188C Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
06/29/2010CA2289600C Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes
06/29/2010CA2274498C Novel expression vectors containing accessory molecule ligand genes and their use for immunomodulation and treatment of malignancies and autoimmune disease
06/29/2010CA2257837C Long-acting galenical formulation for grf peptides
06/29/2010CA2252372C Pathogenic escherichia coli associated protein
06/29/2010CA2236700C Immunity against pasteurella haemolytica leukotoxin
06/29/2010CA2225470C Method and apparatus for inactivating contaminants in blood products
06/29/2010CA2218364C Screening assay for the identification of inhibitors of macrophage migration inhibitory factor
06/29/2010CA2187740C Dna encoding bradykinin b1 receptor
06/29/2010CA2187346C Receptor modulating agents and methods relating thereto
06/29/2010CA2168409C G cap-stabilized oligonucleotides
06/29/2010CA2165271C Reduction of adipose tissue
06/29/2010CA2134030C Soluble interferon .alpha.-receptor, its preparation and use
06/24/2010WO2010071894A2 Tfpi inhibitors and methods of use
06/24/2010WO2010071857A1 Bone grafts with reduced protease activity and methods of selection and use
06/24/2010WO2010071824A2 Methods related to modified glycans
06/24/2010WO2010071807A1 Amide based glucagon superfamily peptide prodrugs
06/24/2010WO2010071769A2 Chimeric l. monocytogens in1b protein
06/24/2010WO2010071217A1 Antibacterial agent for periodontal disease-causing bacteria, and medical or dental material using same
06/24/2010WO2010071190A1 Heparin affinity erythropoietin
1 ... 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 ... 3163